Biopharmaceutical Company Announces Master Plan With Medical Technology Provider

Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company, announced that it has entered into a Device and CMC Development Master Plan with Resyca BV, a medical technology provider. This collaboration is particularly focused on the advancement of Silo's lead candidate, SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD). Resyca BV is a joint venture between Bespak Group and Medspray Pharma BV. Notably, Medspray Pharma BV manufactures a formulation-specific microchip-based spray system chosen by Silo for developing SPC-15. With this new strategic partnership, both companies aim to make advancements in the treatment of PTSD. $Silo Pharma(SILO.US)$